Albany Molecular Research Inc. (AMRI) has posted a fourth quarter loss for 2010 after charges relating to a non-cash goodwill and fixed asset impairment of $35.2m.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Stabilitech, Unilife, Genocea and Amarin.
PPD and Charles River Laboratories (CRL) finished 2010 with very different quarters, each posting results that illustrate trends within the CRO sector.
Global API service provider, ScinoPharm, is to begin the commercial manufacture of vilazodone hydrochloride, the active pharmaceutical ingredient (API) in Clinical Data Inc.'s new antidepressant, Viibryd.
The United States Pharmacopeoia (USP) will help regulators in sub-Saharan Africa ensure drug quality in a new scheme designed to boost testing and analysis capacity.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including a new CEO at Patheon and appointments at Aesica.
Outsourcing-pharma.com presents are round up of the latest expansion in the contracting sector with news from Helix Medical, Carbogen Amicus and A5 Labs.
Israeli drugmaker Teva Pharmaceutical Industries has received a US FDA warning letter criticising laboratory operations at its manufacturing facility in Jerusalem.
US Heparin maker Scientific Protein Laboratories (SPL) says it has resolved “many of the issues” addressed in the US Food and Drug Administration (FDA) warning letter it received late last month.
Sigma-Aldrich has acquired analytical standards and certified reference materials manufacturer Resource Technology Corporation (RTC) to expand its analytical
Ugandan drugmaker Quality Chemicals Industries (QCI) will invest $80m in manufacturing operations to boost capacity for the production of generic AIDS and malaria drugs.
Big pharma has taken a less heavy handed approach to relationships as cutbacks have made outsourcing key, according to Stephen Munk, CEO of Ash Stevens.
Lab Research has signed a non-binding letter of intent (LOI) with a US private equity group interested in acquiring the preclinical contract research organisation (CRO).
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Charles River, AMRI and Synexus.
RecipharmCobra Biologics has received an EU patent for a genetic modification tech that allows antibiotic resistance genes to be removed after insertion is complete.
The EU and US are using substandard medicines as an excuse to tighten IP rules, boosting pharma profits while making it harder for the poor to access drugs, according to Oxfam.
US CRO the Duke Clinical Research Institute (DCRI) has teamed up with Kaplan EduNeering to develop a training programme to meet rising global demand for qualified clinical researchers.
US contract research organisation (CRO) Parexel has cut its 2011 guidance, citing slower backlog conversion from projects generated by “strategic partnerships” as basis for the revision.
Supply chain strategy implementations are more likely to succeed when they have the active support of the board and senior executives, according to research.
Oxford Biomedica has bought RecipharmCobra Biologics’ manufacturing facility in Oxford, UK, to reduce its reliance on third-party production of its gene delivery technology.
Big pharma outsourcing will become much bolder in the next 12-18 months as companies attempt to “dramatically attack cost structures”, according to the Covance CEO.